earnings
confidence high
sentiment neutral
materiality 0.60
Lyell Immunopharma reports Q1 net loss $52.2M; LYL314 RMAT designation and pivotal trial on track
Lyell Immunopharma, Inc.
2025-Q1 EPS reported
-$0.18
revenue$7,000
- Net loss of $52.2M (GAAP) vs $60.7M YoY; non-GAAP net loss $46.3M vs $37.5M YoY.
- Cash, equivalents and marketable securities $330.1M as of Mar 31, 2025; sufficient into 2027.
- R&D expenses $43.4M, G&A $14.0M; workforce reduction and closure of West Hills facility impacted costs.
- LYL314 granted RMAT designation by FDA for relapsed/refractory DLBCL in third-line setting.
- Pivotal trial of LYL314 in third-line expected mid-2025; second-line pivotal trial by early 2026.